Paragon Capital Management (Colorado)’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.3M | Sell |
1,409
-19
| -1% | -$19.3K | 0.27% | 38 |
|
|
2025
Q4 | $1.54M | Buy |
1,428
+1
| +0.1% | +$956 | 0.31% | 33 |
|
|
2025
Q3 | $1.09M | Buy |
1,427
+2
| +0.1% | +$1.49K | 0.2% | 47 |
|
|
2025
Q2 | $1.11M | Buy |
1,425
+2
| +0.1% | +$1.55K | 0.2% | 47 |
|
|
2025
Q1 | $1.18M | Buy |
1,423
+1
| +0.1% | +$832 | 0.24% | 41 |
|
|
2024
Q4 | $1.1M | Buy |
1,422
+1
| +0.1% | +$828 | 0.22% | 40 |
|
|
2024
Q3 | $1.26M | Buy |
1,421
+2
| +0.1% | +$1.8K | 0.25% | 37 |
|
|
2024
Q2 | $1.29M | Buy |
1,419
+19
| +1% | +$15.2K | 0.24% | 35 |
|
|
2024
Q1 | $1.09M | Sell |
1,400
-25
| -2% | -$17.8K | 0.19% | 40 |
|
|
2023
Q4 | $831K | Sell |
1,425
-160
| -10% | -$93.4K | 0.17% | 44 |
|
|
2023
Q3 | $851K | Buy |
1,585
+20
| +1% | +$10.3K | 0.19% | 42 |
|
|
2023
Q2 | $734K | Buy |
1,565
+1
| +0.1% | +$419 | 0.16% | 48 |
|
|
2023
Q1 | $537K | Buy |
1,564
+2
| +0.1% | +$675 | 0.12% | 64 |
|
|
2022
Q4 | $572K | Sell |
1,562
-53
| -3% | -$18.8K | 0.15% | 56 |
|
|
2022
Q3 | $522K | Buy |
1,615
+2
| +0.1% | +$634 | 0.15% | 52 |
|
|
2022
Q2 | $523K | Buy |
1,613
+2
| +0.1% | +$600 | 0.15% | 49 |
|
|
2022
Q1 | $461K | Buy |
1,611
+3
| +0.2% | +$772 | 0.09% | 72 |
|
|
2021
Q4 | $444K | Sell |
1,608
-16
| -1% | -$4.06K | 0.07% | 70 |
|
|
2021
Q3 | $375K | Buy |
1,624
+2
| +0.1% | +$494 | 0.06% | 79 |
|
|
2021
Q2 | $372K | Buy |
1,622
+3
| +0.2% | +$603 | 0.17% | 62 |
|
|
2021
Q1 | $303K | Buy |
1,619
+2
| +0.1% | +$391 | 0.16% | 72 |
|
|
2020
Q4 | $273K | Buy |
1,617
+3
| +0.2% | +$448 | 0.15% | 74 |
|
|
2020
Q3 | $239K | Sell |
1,614
-96
| -6% | -$14.9K | 0.13% | 76 |
|
|
2020
Q2 | $281K | Buy |
1,710
+3
| +0.2% | +$460 | 0.12% | 65 |
|
|
2020
Q1 | $237K | Buy |
1,707
+3
| +0.2% | +$412 | 0.13% | 58 |
|
|
2019
Q4 | $224K | Buy |
+1,704
| New | +$198K | 0.12% | 161 |
|
|
2019
Q2 | – | Sell |
-1,693
| Closed | -$220K | – | 171 |
|
|
2019
Q1 | $220K | Buy |
+1,693
| New | +$206K | 0.13% | 163 |
|
|
2018
Q4 | – | Sell |
-1,888
| Closed | -$203K | – | 230 |
|
|
2018
Q3 | $203K | Buy |
+1,888
| New | +$189K | 0.17% | 197 |
|
|
2015
Q4 | – | Sell |
-4,736
| Closed | -$396K | – | 84 |
|
|
2015
Q3 | $396K | Sell |
4,736
-296
| -6% | -$25K | 0.24% | 46 |
|
|
2015
Q2 | $420K | Buy |
5,032
+3
| +0.1% | +$229 | 0.26% | 46 |
|
|
2015
Q1 | $365K | Buy |
+5,029
| New | +$358K | 0.24% | 49 |
|
|
2014
Q4 | – | Sell |
-5,012
| Closed | -$325K | – | 72 |
|
|
2014
Q3 | $325K | Sell |
5,012
-195
| -4% | -$12.3K | 0.23% | 48 |
|
|
2014
Q2 | $324K | Buy |
5,207
+78
| +2% | +$4.65K | 0.22% | 48 |
|
|
2014
Q1 | $302K | Sell |
5,129
-1,054
| -17% | -$58.8K | 0.22% | 51 |
|
|
2013
Q4 | $315K | Buy |
6,183
+4
| +0.1% | +$200 | 0.23% | 45 |
|
|
2013
Q3 | $311K | Buy |
6,179
+5
| +0.1% | +$262 | 0.24% | 47 |
|
|
2013
Q2 | $303K | Buy |
+6,174
| New | +$336K | 0.24% | 51 |
|
Other funds holding LLY
VCM
VPM
Paragon Capital Management (Colorado)'s LLY Position: Q1 2026 in Review
Paragon Capital Management (Colorado) reduced its Eli Lilly (LLY) stake by 1.3% in Q1 2026, selling an estimated $19.3K and leaving 1,409 shares worth $1.3M. The position accounts for 0.27% of the portfolio, ranked #38.
Paragon Capital Management (Colorado) first reported a position in LLY in Q2 2013 and has held it in 37 quarters since. The position peaked at $1.54M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Paragon Capital Management (Colorado) held 1,409 shares of Eli Lilly worth $1.3M as of Q1 2026.
- Paragon Capital Management (Colorado) sold 19 Eli Lilly shares in Q1 2026, an estimated $19.3K.
- Eli Lilly made up 0.27% of Paragon Capital Management (Colorado)'s portfolio in Q1 2026, its #38 holding.
- Paragon Capital Management (Colorado) first reported a position in Eli Lilly in Q2 2013 and has held it in 37 quarters since.
- Paragon Capital Management (Colorado)'s Eli Lilly position peaked at $1.54M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Paragon Capital Management (Colorado)'s 13F filing for Q1 2026, filed 15 Apr 2026.